A Phase 2 interventional study of CLDN6 CAR-T and CLDN6 RNA-LPX in Testicular Germ Cell Tumor and Extragonadal Germ Cell Tumor, sponsored by BioNTech SE. Withdrawn. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-02.
Sponsored by BioNTech SE · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is designed to evaluate the safety, efficacy, cellular kinetics, and immunogenicity of Claudin 6 (CLDN6) Chimeric antigen receptor T cell (CAR-T) ± CLDN6 ribonucleic acid-lipoplex (RNA-LPX) in participants born male with relapsed or refractory CLDN6-positive testicular or extragonadal germ cell tumors (GCTs) after prior salvage therapy.
The study will consist of two parts. The Safety Lead-in Part will evaluate safety and tolerability of CLDN6 CAR T ± CLDN6 RNA-LPX therapy in three arms with different dosing regimens. In the Safety Lead-in Part, participants will be randomized in a 1:1:1 ratio. Data from the Safety Lead-in Part up to the cut off will be used to select the dose for the single-arm Main Part of the study.
To increase the potency of the transferred CAR-T cells, a lymphodepleting chemotherapy regimen (comprising fludarabine and cyclophosphamide) will be administered in participants prior to infusion of CLDN6 CAR-T.
It is expected that it will take approximately 28 months for each participant to complete screening, apheresis, pre-treatment, treatment, and primary follow-up.
Participants who receive a CLDN6 CAR-T infusion will complete the long-term follow-up (LTFU) to assess safety and efficacy of the CLDN6 CAR-T treatment for a total of 15 years after CLDN6 CAR-T infusion. No investigational medicinal product (IMP) will be administered during the LTFU.
85 studies on the registry are indexed under Testicular Germ Cell Tumor; 10 are open to participants now.
Browse Testicular Germ Cell Tumor studies →BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Participants with evidence of progressive or recurrent GCT defined as meeting at least one of the following criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: CLDN6 CAR-T · Biological: CLDN6 RNA-LPX
Biological: CLDN6 CAR-T
Biological: CLDN6 CAR-T · Biological: CLDN6 RNA-LPX
Doses as selected from the Safety Lead-in Part
Biological: CLDN6 CAR-T · Biological: CLDN6 RNA-LPX
Intravenous (IV) infusion
IV injection
Safety Lead-in Part: Occurrence of treatment emergent adverse events (TEAEs) including Grade ≥3, adverse events of special interest (AESIs) and serious or fatal TEAEs by casual relationship to study treatment
For each treatment arm
Time frame: Up to 110 weeks after first dose of IMP
Main Part: Overall response rate (ORR) assessed by the blinded independent central review (BICR)
Defined as the percentage of participants in whom a confirmed complete response (CR) or partial response (PR) (per response evaluation criteria in solid tumors version 1.1 (\[RECIST 1.1\]) is observed as best overall response
Time frame: Up to 110 weeks after first dose of IMP
LTFU: Occurrence of AEs suspected to be related to CLDN6 CAR-T
AEs may include: new malignancy (hematologic or solid) from genetically modified cells; new neurologic disorder, or exacerbation of a pre-existing disorder; new rheumatologic or autoimmune disorder, or exacerbation of a prior rheumatologic or other autoimmune disorder; new hematologic disorder; other new clinical condition considered by the investigator to be related to the prior genetically engineered T-cell therapy.
Time frame: Up to 15 years after CLDN6 CAR-T administration
Safety Lead-in and Main Part: Occurrence of TEAEs including Grade ≥3, AESIs, and serious or fatal TEAEs by casual relationship to study treatment
For each treatment arm
Time frame: From first dose of IMP until 90 days after last dose of IMP, or until a new anticancer therapy is started, whichever occurs first
Safety Lead-in and Main Part: Geometric mean of pharmacokinetic parameter maximum concentration (Cmax) of CLND6 CAR-T
For each treatment arm using CLND6 CAR-T concentration in blood
Time frame: Up to 97 weeks after first IMP dose
Main Part: Geometric mean of pharmacokinetic parameter Cmax of interleukin (IL)-6
From baseline until last available sample
Time frame: Up to 97 weeks after first IMP dose
Safety Lead-in and Main Part: Geometric mean of pharmacokinetic parameter time to maximum concentration (Tmax) of CLND6 CAR-T
For each treatment arm using CLND6 CAR-T concentration in blood
Time frame: Up to 97 weeks after first IMP dose
Main Part: Geometric mean of pharmacokinetic parameter Tmax of IL-6
From baseline until last available sample
Time frame: Up to 97 weeks after first IMP dose
Safety Lead-in and Main Part: Geometric mean of pharmacokinetic parameter area under the time concentration curve (AUC) of CLND6 CAR-T
For each treatment arm using CLND6 CAR-T concentration in blood
Time frame: Up to 97 weeks after first IMP dose
Safety Lead-in and Main Part: Overall response rate (ORR) assessed by the investigator
Defined as the percentage of participants in whom a confirmed complete response (CR) or partial response (PR) is observed as best overall response. Tumor response will be assessed by the investigator per RECIST 1.1. In the Safety Lead-in Part, tumor assessment will also be made based on reduction of the serum tumor marker(s) (alpha fetoprotein \[AFP\]/beta human chorionic gonadotropin \[βhCG\]).
Time frame: Up to 110 weeks after first dose of IMP
Safety Lead-in and Main Part: Disease control rate (DCR) assessed by the investigator
Defined as the percentage of participants in whom a CR, PR, or stable disease (SD) is observed as best overall response. Tumor response will be assessed per RECIST 1.1. In the Safety Lead-in Part, tumor assessment will also be made based on reduction of the serum tumor marker(s) (alpha fetoprotein \[AFP\]/beta human chorionic gonadotropin \[βhCG\]).
Time frame: Up to 110 weeks after first dose of IMP
Main Part: DCR assessed by BICR
Defined as the percentage of participants in whom a CR, PR, or SD is observed as best overall response. Tumor response will be assessed per RECIST 1.1
Time frame: Up to 110 weeks after first dose of IMP
Main Part: Progression-free survival (PFS) assessed by the investigator
Defined as the time from first dose of CLDN6 CAR-T to progressive disease (PD) or death from any cause, whichever occurs first. Tumor response will be assessed per RECIST 1.1
Time frame: Up to 110 weeks after first dose of IMP
Main Part: PFS assessed by BICR
Defined as the time from first dose of CLDN6 CAR-T to PD or death from any cause, whichever occurs first. Tumor response will be assessed per RECIST 1.1
Time frame: Up to 110 weeks after first dose of IMP
LTFU: PFS assessed by the investigator
Defined as the time from first dose of CLDN6 CAR-T to first objective progressive disease per RECIST 1.1 and/or based on reduction of the serum tumor marker(s) (AFP/βhCG), or death from any cause, whichever occurs first.
Time frame: Up to 15 years after the last IMP administration
Main Part: Duration of response (DOR) assessed by the investigator
Defined as the time from first objective response (CR or PR) to first occurrence of tumor progression, or death from any cause, whichever occurs first. Tumor response will be assessed per RECIST 1.1.
Time frame: Up to 110 weeks after first dose of IMP
Main Part: DOR assessed by BICR
Defined as the time from first objective response (CR or PR) to first occurrence of tumor progression, or death from any cause, whichever occurs first. Tumor response will be assessed per RECIST 1.1.
Time frame: Up to 110 weeks after first dose of IMP
Main Part: Overall survival (OS)
Defined as the time from first dose of CLDN6 CAR-T to death from any cause
Time frame: Up to 97 weeks after first dose of IMP or until death, whichever occurs first
LTFU: OS
Defined as the time from first dose of CLDN6 CAR-T to death from any cause
Time frame: Up to 15 years from last genetically engineered T-cell infusion or until death, whichever occurs first
Main Part: Percentage of participants with pre-existing anti-chimeric antigen receptor (CAR) antibodies prior to CLDN6 CAR-T infusion
For each treatment arm using CLND6 CAR-T concentration in blood and of IL-6 from baseline until last available sample
Time frame: On Day 1 prior to CAR-T infusion
Main Part: Percentage of participants with treatment-emergent anti-CAR antibodies post-CLDN6 CAR-T infusion until last available sample
Anti-CAR antibodies including both treatment-induced and treatment-boosted
Time frame: Up to 97 weeks after first dose of IMP
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2025; primary completion for Jun 2042, 203 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.